UNSPSC 51422302: Beclometasone or Beclomethasone

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H29ClO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KGZ1SLC28Z, chemically known as 9-chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione but generally known as beclometasone, which bears US NIH Compound Identifier 20469. Beclometasone most often comes in base, 17,21-dipropionate, and propionate forms.

UNSPSC 51422302 Beclometasone or Beclomethasone is a Commodity code that state and local governments use to classify inhaled corticosteroid medications for respiratory conditions, though recent procurement activity under this code shows a significant mismatch with its nominal pharmaceutical scope. The single recent opportunity in the available dataset—Seminole County, Florida's IFB60459723LAS—solicits naloxone and drug deactivation systems rather than beclometasone, indicating either a tagging error in the source data or inconsistent code application by the issuing body. County health departments and community health agencies represent the primary issuing bodies under this code when pharmaceutical procurements are accurately classified, typically seeking regular supply agreements for respiratory medications to support clinical and emergency-response programs.

Seminole County, Florida posted the only recent opportunity on June 30, 2026, with a response deadline of July 26, 2023 (a date that has passed). The county sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Bidders were required to submit pricing electronically, include all shipping and delivery costs, comply with drug-free workplace certification and E-Verify requirements, and maintain workers' compensation and liability insurance. The contract carried a two-year initial term with an optional one-year renewal and included a three-month probationary period. Given the scope mismatch between the code's pharmaceutical definition and the naloxone procurement actually posted, this code shows little relevant recent state and local activity for inhaled corticosteroid products; business development professionals should confirm whether their firm's beclometasone offerings align with how their target state and local jurisdictions actually tag pharmaceutical solicitations, as application inconsistency appears to be a factor in code selection.